P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy

scientific article published on 22 September 2016

P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JTHO.2016.08.110

P50authorJean-Charles SoriaQ33120580
Enriqueta FelipQ56605610
P2093author name stringJin Zhang
Natasha Leighl
Amita Patnaik
Bilal Piperdi
Joseph P Eder
Myung-Ju Ahn
Edward B Garon
Leena Gandhi
Charu Aggarwal
Leora Horn
Rina Hui
Suresh Ramalingam
Enric Carcereny
Matthew Hellmann
Gregory M Lubiniecki
Matthew Gubens
Gary W Middleton
Ani S Balmanoukian
P433issue10S
P921main subjectimmunotherapyQ1427096
non-small-cell lung carcinomaQ3658562
pembrolizumabQ13896859
P304page(s)S241-S242
P577publication date2016-09-22
P1433published inJournal of Thoracic OncologyQ2448056
P1476titleP2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy
P478volume11

Reverse relations

cites work (P2860)
Q47825909Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature.
Q47718879Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Q89748459Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Q92890675Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response
Q52723409Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Q55312983Immunotherapy in the Asiatic population: any differences from Caucasian population?
Q42340575Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?
Q47422615PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Q42329095Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
Q55194789Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.
Q42359757The KEY to the end of chemotherapy in non-small cell lung cancer?
Q37669352Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context

Search more.